Greg O. Cron1,2,3, Beckie Manouchehri4, Andrew Boivin3, Nader Zakhari1,3, Brandon Zanette5,6, Gerard H. Jansen1,2,3, John Woulfe1,2,3, Rebecca E. Thornhill1,2,3, Andreas Greiser7, Ian G. Cameron1,2,3,4, and Thanh B. Nguyen1,2,3
1The Ottawa Hospital, Ottawa, ON, Canada, 2Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4Carleton University, Ottawa, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada, 7Siemens Healthcare GmbH, Erlangen, Germany
After a patient has received treatment for a high grade glioma, a new
enhancing lesion presents a common diagnostic dilemma: Malignant tumor
recurrence and benign treatment-related changes (TRC) appear similar on
conventional MRI. MRI tracer kinetic studies may help distinguish recurrence
from TRC. We investigated whether Ktrans measurements using quantitative
DCE-MRI can accurately diagnose recurrence. We also studied the effect of
the DCE T1 mapping method (VFA versus LL). Ktrans values in recurrent
tumor were higher than in TRC, providing sensitivity of 69-77%,
specificity of 100%. The choice of T1 mapping had little effect on
diagnostic accuracy.
